DB
BPMC

Danske Bank’s Blueprint Medicines BPMC Stock Holding History

Danske Bank’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-300
Closed -$38.5K – 1502
2025
Q2 		$38.5K Hold
300
– – ﹤0.01% 1086
2025
Q1 		$26.6K Hold
300
– – ﹤0.01% 981
2024
Q4 		$26.2K Sell
300
-800
-73% -$73.3K ﹤0.01% 989
2024
Q3 		$102K Buy
+1,100
New +$109K ﹤0.01% 1010

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Danske Bank's BPMC Position: Q3 2025 in Review

Danske Bank sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 300 shares — an estimated $38.5K sold.

Danske Bank first reported a position in BPMC in Q3 2024 and held it in 4 quarters. The position peaked at $102K in Q3 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Danske Bank reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Danske Bank sold 300 Blueprint Medicines shares in Q3 2025, an estimated $38.5K.
  • Danske Bank first reported a position in Blueprint Medicines in Q3 2024 and held it in 4 quarters.
  • Danske Bank's Blueprint Medicines position peaked at $102K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Danske Bank's 13F filing for Q3 2025, filed 13 Nov 2025.